DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20190149

A comparative study of the efficacy of amisulpride and olanzapine in patients with schizophrenia attending the outpatient Department of Psychiatry in a tertiary care hospital, Silchar, Assam, India

Ali N. Yashin, Dolly Roy, Prosenjit Ghosh

Abstract


Background: Schizophrenia is one of the most commonly encountered psychiatric disorders. It is characterized by impairment in perception or expression of reality, leading to occupational and social dysfunction. Now a day’s mainstay of treatment of schizophrenia is by using atypical antipsychotics. Amisulpride and olanzapine are atypical antipsychotics which are commonly used in treatment of schizophrenia. The current study is undertaken to assess the efficacy of amisulpride which is a relatively newer antipsychotics against existing antipsychotic olanzapine.

Methods: This was designed as a single-blind, prospective, parallel-group, observational study. Eighty adult patients of either sex were randomized to receive standard doses of the two drugs orally for 12 weeks, with follow up at 4 and 8 weeks. Effectiveness was assessed by change in the score of Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) score during the treatment period. Data were entered in Microsoft excel and statistical analysis were done using graph pad and p value <0.05 considered to be statistically significant.

Results: Out of 80 adults patients 76 patients were evaluated by dividing into two groups, 38 patients were included in each group. Final BPRS score was less for olanzapine as compared to amisulpride (p<0.001). Improvement in CGI score is more in olanzapine group than amisulpride group which became statistically significant from 8th weeks onwards.

Conclusions: Both amisulpride and olanzapine are very effective in controlling the symptoms of schizophrenia which is evident by significant decrease in BPRS, CGI-S and CGI-I score, but efficacy of amisulpride is still inferior to olanzapine.


Keywords


Amisulpride, Atypical antipsychotics, Olanzapine, Schizophrenia

Full Text:

PDF

References


American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association; 2000.

Reus VI. Mental disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrisons’s principle of internal medicine, 16th ed. New York: McGraw-Hill, 2005:2559-60.

Messias E, Mourao C, Maia J, Campos JP, Ribeiro K, Ribeiro L, et al. Season of birth and schizophrenia in Northeast Brazil: relationship to rainfall. J Nerve Ment Dis. 2006;194(11):870-3.

Carpenter WT. Jr, Buchanan RW. Schizophrenia. N Engl J Med. 1994;330(10):681-90.

Tamminga CA, Thakar GK, Medoff DR. Neuropsychiatric Aspects of schizophrenia. Textbook of Neuropsychopharmacology, 4th ed. Washington DC: American Psychiatric Press, 2001.

Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998 Jul 1;173(1):11-53.

Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997 Dec 1;171(6):502-8.

Lieberman JA. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators; Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.

Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. Journal of Pharmacology and Experimental Therapeutics. 1997 Jan 1;280(1):83-97.

Central Drugs Standard Control Organization. New drug approvals in India in 2006 (monograph on the internet). New Delhi: Central Drugs Standard Control Organization; 2006. Available at: http://cdsco.nic.in/new_drugs_app6.html.

Thomas S, editor. Drug reference for FDA approved psychiatric drugs (monograph on the internet). Quincy, Illinois: Neurotransmitter.net; 2009. Available at: http://www.neurotransmitter.net/drug reference.html.

Cerit C, Vural M, Bos Gelmez SU, Ozten E, Aker AT, et al. Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study. Psychopharmacol Bull. 2010 Jan 1;43(4):22-36.

US Food and Drug Administration. 2004 safety alert on Zyprexa (olanzapine). Rockville, MD: US Food and Drug Administration Med Watch Programme, 2004. Available at: http://www.fda.gov/med Watch/ SAFETY/2004/zyprexa.htm.

Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.

Leon AC, Shear MK, Klerman GL, Portera L, Rosenbaum JF, Goldenberg I. A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression. J Clin Psychopharmacol. 1993;13(5):327-3

Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the clinical Global Impression (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159-71.

Zaider TI, Heimberg RG, Fresco DM, Schneier FR, Liebowitz MR. Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med. 2003 May;33(4):611-22.

Bhowmick S, Hazra A, Ghosh M. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Australian New Zealand J Psychiatry. 2010 Jan 1;44(3):237-42.

Martin S, Loo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot O, et al. SOLIANOL Study Group: A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: Short-term results at two months. Curr Med Res Opin. 2002;18(6):355-62.

Pawar GR, Phadnis P, Paliwal A. Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-Week, double-blind, single-centre, prospective clinical trial. ISRN Psychiatry. 2012 Mar 14;2012.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987 Jan 1;13(2):261-76.

Mortimer A, Martin S, Lôo H, Peuskens J. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004 Mar 1;19(2):63-9.

Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6‐month double‐blind controlled clinical trial. Acta Psychiatr Scand. 2006 Nov;114(5):319-27.

Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) Study. CNS Drugs. 2006 Apr 1;20(4):293-301.